| 000 | 01665 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515233948.0 | ||
| 264 | 0 | _c20110325 | |
| 008 | 201103s 0 0 eng d | ||
| 022 | _a1473-5571 | ||
| 024 | 7 |
_a10.1097/QAD.0b013e32833d214c _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDelaugerre, Constance | |
| 245 | 0 | 0 |
_aTime course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. _h[electronic resource] |
| 260 |
_bAIDS (London, England) _cSep 2010 |
||
| 300 |
_a2391-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAntiretroviral Therapy, Highly Active |
| 650 | 0 | 4 |
_aDNA, Circular _xdrug effects |
| 650 | 0 | 4 |
_aDNA, Viral _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV Long Terminal Repeat _xdrug effects |
| 650 | 0 | 4 |
_aHIV-1 _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPyrrolidinones _xadministration & dosage |
| 650 | 0 | 4 | _aRaltegravir Potassium |
| 650 | 0 | 4 | _aSequence Analysis, DNA |
| 650 | 0 | 4 | _aViral Load |
| 650 | 0 | 4 | _aViremia |
| 700 | 1 | _aCharreau, Isabelle | |
| 700 | 1 | _aBraun, Josephine | |
| 700 | 1 | _aNéré, Marie-Laure | |
| 700 | 1 | _ade Castro, Nathalie | |
| 700 | 1 | _aYeni, Patrick | |
| 700 | 1 | _aGhosn, Jade | |
| 700 | 1 | _aAboulker, Jean-Pierre | |
| 700 | 1 | _aMolina, Jean-Michel | |
| 700 | 1 | _aSimon, François | |
| 773 | 0 |
_tAIDS (London, England) _gvol. 24 _gno. 15 _gp. 2391-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/QAD.0b013e32833d214c _zAvailable from publisher's website |
| 999 |
_c20022200 _d20022200 |
||